. Other genes are regulated selectively by either LXR (e.g., ABCA1) or SREBP-1c (e.g., FAS). Dietary polyunsaturated fatty acids suppress both LXR and SREBP-1c but are also crucial to StAR expression (6) . It is notable that the proteolytic activation of SREBP-1c, unlike that of other SREBPs, is regulated by insulin and probably not suppressed by cholesterol (10) .
Little is known about the physiological ligands for LXR. However, there is evidence that mitochondrial cholesterol metabolism may be a source of these activators. StAR may therefore also participate as an activator of LXR activity. The steroid intermediate 22R-hydroxycholesterol, which is formed by CYP11A1, is a potent LXR agonist but is unlikely to be released from the mitochondrial cholesterol-cleavage process. However, StAR can also mediate cholesterol transfer to mitochondrial cholesterol hydroxylases that may generate LXR agonists. Other members of the StAR family - StARD4 and StARD5 - exhibit cholesterol transfer activity in steroidogenic cells and macrophages, respectively (11) . Interestingly, elevation of these StAR relatives (and perhaps also of StAR) causes LXR activation, possibly by forming a hydroxysterol agonist. Hydroxysterols also stimulate StAR expression in steroidogenic cells (12) , possibly through this new LXR mechanism.
This connection between LXR and StAR, introduced in this issue of the JCI by Cummins et al. (5) , provides a new avenue for regulation of steroid synthesis. This may extend to other steroidogenic processes, including testosterone synthesis in the Leydig cells of the testis, estrogens in the ovary, and even neurosteroids produced in glial cells of the brain, each of which utilize StAR. It should be noted that cholesterol homeostasis in human adrenals is primarily mediated by LDL rather than HDL (13) . It remains to be determined whether the LXR gateway to StAR and steroid synthesis remains open in tissues where cholesterol fluxes are less than in the adrenal or when the LDL pathway partially bypasses the lipid droplets (see Figure 1 ).
New insights into the regulation of inflammation by adenosine There is growing interest in elucidating the mechanisms by which adenosine inhibits the immune system, since these inhibitory adenosine receptors and their downstream signaling pathways are promising targets for new antiinflammatory therapies. By signaling through the A 2A adenosine receptor (A 2A AR), adenosine suppresses the immune system, primarily by inhibiting lymphoid or myeloid cells including neutrophils (1), macrophages (2), lymphocytes (3, 4) , and platelets (5) . These responses are amplified by rapid induction of A 2A AR mRNA in macrophages and T lymphocytes in response to inflammatory or ischemic stimuli (2, 3, 6, 7). The A 2B adenosine receptor (A 2B AR) also appears to mediate antiinflammatory effects in macrophages by inhibiting the production of TNF-α and IL-1β, stimulating IL-10 and inhibiting macrophage proliferation (8-11) ( Figure 1A ). Macrophage A 2B AR signaling increases during inflammation, as the macrophage-activating cytokine IFN-γ causes induction of macrophage A 2B AR mRNA (12) . However, the A 2B AR is somewhat unusual in that it is dually coupled to the generally antiinflammatory G protein G s and the generally proinflammatory G protein G q (13) ; in addition, numerous proinflammatory effects mediated by activation of the A 2B AR have also been described (Table 1) . 
Future questions
It will also be of interest in future studies to examine the response of the A 2B AR Table 1 , activation of the A2BAR stimulates IL-6 and other proinflammatory cytokines. Hypoxia increases the intracellular production of adenosine, which is transported outside the cell by nucleoside transport proteins. Hypoxia and possibly activation of the A2BAR stimulate the release of ATP and the production of the A2BAR and ectoenzymes (CD39 and CD73) that convert ATP to adenosine. Vasodilation in response to A2BAR activation may increase shear stress to stimulate ATP release.
knockout mouse in the setting of hypoxia or ischemia, which elicit the accumulation of large levels of adenosine. A selective A 2B AR antagonist blocks myocardial preconditioning when applied to the isolated rabbit heart after ischemia (20) . This could occur either because A 2B ARs on the heart mediate cardioprotection or, as discussed above, because A 2B AR activation facilitates the release and/or metabolism of adenine nucleotides to indirectly enhance adenosine production. The latter scheme is consistent with the observation that myocardial preconditioning has a remote adenosine-mediated effect on platelet function (21) .
In conclusion, the study by Yang et al. (14) bolsters the conclusion that activation of A 2B ARs on certain cells, particularly macrophages, inhibits inflammation. A proinflammatory phenotype noted at rest is somewhat unexpected, and the mechanism underlying this inflammation is not yet known. In view of a number of previous reports indicating that A 2B AR activation can be proinflammatory (Table 1) , it will be of interest to use the newly available A 2B AR knockout mouse in order to determine whether A 2B AR activation on different cells can elicit both pro-and antiinflammatory responses.
